414 reports of this reaction
3.2% of all ICATIBANT ACETATE reports
#3 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #3 most commonly reported adverse reaction for ICATIBANT ACETATE, manufactured by Takeda Pharmaceuticals America, Inc.. There are 414 FDA adverse event reports linking ICATIBANT ACETATE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 3.2% of all 12,796 adverse event reports for this drug.
Patients taking ICATIBANT ACETATE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is moderately reported among ICATIBANT ACETATE users, representing a notable but not dominant share of adverse events.
In addition to product dose omission issue, the following adverse reactions have been reported for ICATIBANT ACETATE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 414 FDA reports for ICATIBANT ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 3.2% of all adverse event reports for ICATIBANT ACETATE, making it one of the most commonly reported side effect.
If you experience product dose omission issue while taking ICATIBANT ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.